Carboxy-PTIO, potassium salt|148819-94-7|-陌孚医药/Medlife

您当前的位置：

Carboxy-PTIO, potassium salt

目录号: PC15163 纯度: ≥98%

CAS No. :148819-94-7

商品编号	规格	价格	会员价
PC15163-10mg	10mg	¥1146.60	请登录
PC15163-50mg	50mg	¥4783.38	请登录
PC15163-100mg	100mg	¥8355.48	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Carboxy-PTIO, potassium salt
中文别名	2-4-羧苯基四甲基咪唑烷-1-氧-3-氧化物;2-(4-羧基苯基)-4,4,5,5-四甲基咪唑啉-1-氧-3-氧化钾盐;2-(4-羧基苯基)-4,4,5,5-四甲基咪唑啉-3-氧化钾盐;2 - (4 -羧基苯基)-4,4,5,5 -四甲基咪唑啉-3 -氧化钾盐
英文名称	Carboxy-PTIO, potassium salt
英文别名	1H-Imidazol-1-yloxy,2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-, 3-oxide, potassium salt(1:1);1H-Imidazol-1-yloxy,2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-, 3-oxide, potassium s...;Carboxy-PTIO (potassium salt);Carboxy-PTIO, Potassium Salt;CARBOXY-PTIO;CARBOXY-PTIO POTASSIUM;CARBOXY-PTIO POTASSIUM (2-(4-CARBOXYPHEN YL)-4,4,5,5-TETRAMETHYLIM;2-(4-CARBOXYPHENYL)-4,4,5,5-TETRAMETHYL-IMIDAZOLINE-1-OXYL-3-OXIDE POTASSIUM;Carboxy-PTIO2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide;2-(4-CARBOXYPHENYL)-4,4,5,5-TETRAMETHYLIMIDAZOLINE-1-OXYL-3-OXIDE, POTASSIUM SALT;2-(4-CARBOXYPHENYL)-4,5-DIHYDRO-4,4,5,5-TETRAMETHYL-1H-IMIDAZOL-1-YLOXY-3-OXIDE POTASSIUM;2-(4-CARBOXYPHENYL)-4,5-DIHYDRO-4,4,5,5-TETRAMETHYLIMIDAZOLINE-3-OXIDE-1-OXYL, POTASSIUM SALT;Carboxy-PTIO,98%
Cas No.	148819-94-7
分子式	C₁₄H₁₇N₂O₄-^.K+
分子量	316.39
包装储存	-20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

生物活性

Carboxy-PTIO potassium is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO₂. Carboxy-PTIO potassium can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.

性状

Solid

体外研究(In Vitro)

Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) significantly suppresses the stimulation of NO expression induced by physalin A treatment, but no change is observed in Carboxy-PTIO treatment alone.
Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) reduces physalin A-induced cleavage of procaspase-3 and PARP, down-regulated ICAD expression,diminishing DNA fragmentation in nuclei.
Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) shows no effect on iNOS expression. However, decreased-mTOR and p-mTOR levels induced by physalin A is reversed by Carboxy-PTIO with concomitant suppression of LC3 I to LC3 II conversions in A375-S2 cells .

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	A375-S2 cells
Concentration:	200 μM
Incubation Time:	1 h prior to physalin A; 24 hours
Result:	Diminished physalin A-induced procaspase-3 and PARP cleavage.

体内研究(In Vivo)

Carboxy-PTIO (intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min) treatment improves the hypotension, renal dysfunction and survival rate in Lps-treated rats. But it does not affect each parameter in naomal rats.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SD rats
Dosage:	0.056-1.70 mg/kg/min
Administration:	Intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min
Result:	Exhibited a potent therapeutic value in endotoxin shock through the direct scavenging action against NO.

运输条件

Room temperature or refrigerated transportation.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

[1]. Hao He, et al.Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells.Food Chem Toxicol. 2014 Sep;71:128-35. [Information]

[2]. T Akaike, et al. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry. 1993 Jan 26;32(3):827-32. [Information]

[3]. M Yoshid, et al. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. Biochem Biophys Res Commun. 1994 Jul 29;202(2):923-30. [Information]

溶解度数据

体外研究:

H₂O : 25 mg/mL (79.27 mM; ultrasonic and warming and heat to 60°C)

DMSO : 10 mg/mL (31.71 mM; ultrasonic and warming and heat to 60°C)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1707 mL	15.8534 mL	31.7068 mL
5 mM	0.6341 mL	3.1707 mL	6.3414 mL
10 mM	0.3171 mL	1.5853 mL	3.1707 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 50 mg/mL (158.53 mM); Clear solution; Need ultrasonic

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation